Dynamics of endogenous interferon-alpha and -gamma production under the influence of ingaron therapy in patients with chronic epstein – barr viral infection with chronic fatigue syndrome

Abstract

The influence of antiviral therapy with ingaron on the dynamics of production of interferons and and clinical effects in patients with chronic viral Epstein Barr infection was studied. The study involved 51 patients (33 women and 17 men aged 35,27 1,28 years) suffering from chronic infection caused by the Epstein Barr virus. The duration of the disease from the appearance of the first complaints to laboratory confirmation of the Epstein Barr virus infection and diagnosis was 2,23 0,21 years. Determined the serum, spontaneous and induced production of cytokines interferons and in serum and in the culture of lymphocytes. Three months after the end of antiviral therapy, in patients with an initially low level of induced interferon-, the production of interferon- increased. The absence of an increase in the production of induced interferon- in patients one and three months after the end of therapy with ingaron indicates the absence of the effect of the drug on the level of endogenous interferon-. It has been established that the initially low level of induced interferon- can be a marker of the positive effect of the therapy with ingaron. Correlation analysis revealed the effect of baseline interferon- induced on the clinical picture of the disease. Thus, initially a high level of induced interferon- (2706 1058.94 pg/ml) inversely affects the development of sweating in patients (r = 0.506, p = 0,023; = 0.419, р = 0.021), and initially low level of the induced IFN- (287.2 64.65 pg/ml) on development of weakness (r = 0.405, р = 0.045; = 0.419, р = 0.037). In general, ingarone can be used in the therapy of patients with chronic Epstein virus Bar infection at a dose of 500,000 IU every other day, at least 10 injections.